\
&
Contact us
\
&
Contact us
Published on | 3 months ago
Programmes Security Digital, Industry & Space AI Continent CybersecurityThe European Commission has opened a call for evidence to collect research and best practices on how to simplify its legislation, especially when it comes to data, cybersecurity and artificial intelligence (AI).
This initiative is part of the Commission’s simplification agenda and efforts to create a more favourable business environment, by lightening administrative burdens and costs on companies. The initiative also supports the Commission’s target in the Competitiveness Compass to cut administrative burden by at least 25% for all companies and at least 35% for small and medium-sized enterprises.
This call for evidence follows extensive stakeholder engagement that included public consultations on the Data Union Strategy, the Cybersecurity Act revision, and on the Apply AI Strategy. It is a first step in simplifying the EU’s digital rulebook and remains open until 14 October 2025.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
